Basking Ridge, NJ-based Regado Biosciences has raised $11.6 million, according to a regulatory filing. The company’s lead compound is an anticoagulant for patients suffering from acute coronary syndrome. It is also working on a treatment for venous thrombosis and is searching for antiplatelet therapies. The most recent funding was part of a $21.5 million round. The company previously raised $23 million in 2007 and $20 million in 2005. Its investors include Caxton Advantage Life Sciences Fund, Quaker BioVentures, and Domain Associates.
